Author:
GÜNDÜZ Ramazan,YİLDİZ Bekir Serhat,ÖZDEMIR İbrahim Halil,ÖZEN Mehmet Burak,ÇETIN Nurullah,YAVUZGİL Oğuz
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference16 articles.
1. 1. Laposata M, Green K, Elisabeth MJAPLM. College of American Pathologist Conference XXXI on laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
2. 2. Handeland G, Abildgaard U, Holm H, Arnesen KJEjocp. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-12.
3. 3. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux J, Kher A, Aiach M, Fiessinger J, Thrombosis F-SGJ, haemostasis. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis.Thromb Haemost. 1994;72:698-702.
4. 4. Boneu BJT, haemostasis. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost. 1994;72:330-4.
5. 5. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane GJTr. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res. 2007;120:347-51.